Radioiodine (RAI) in Combination With Durvalumab (Medi4736) for RAI-avid, Recurrent/Metastatic Thyroid Cancers
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Durvalumab (Primary) ; Thyrotropin alfa
- Indications Thyroid cancer
- Focus Adverse reactions
- 17 Jul 2024 Planned End Date changed from 1 Jul 2024 to 1 Jul 2025.
- 30 Jun 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 30 Jun 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.